Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary
Kura Oncology launches Caspian Therapeutics with $50 million financing to advance menin inhibitor for diabetes and cardiometabolic diseases.
Kura Oncology is splitting off a new company called Caspian to focus on treating diabetes using a special medicine. This shows the company believes in this new direction, but it's unclear yet if this medicine will actually work or help patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.